The head of the Cedars-Sinai physician-researcher found the bomocar – the protein found in the blood – the most common heart failure, JAMA Cardiology Shows.
Heart failure with the Protective Operating fraction (HFPEF) affects 6.5 million US dollars annually. And now, thanks to the first biomarker detection for HFPEF, a simple blood test may reveal whether the patient's heart is sufficiently important protein. If the protein level decreases, the signal of the bimirragon is increased and the doctors can diagnose heart failure, fix corrective medication and prevent further progress of the disease.
"The symptoms of cardiac failure are developing, the critical window is typically closed corrective therapy," said Robin Shaw, MD, PhD, Wasserman, chair of cardiology and professor of medicine at Smidt Heart Institute Cedars-Sinai and Principal Investigator Research. "Our discovery allows not only the diagnosis of the disease but also the treatment of patients than the critical period of early intervention in the spine of the vitality."
Heart failure is maintained under the swelling faction, where the heart is compressed, but the problems have a relaxation ability – limiting the ability of the heart to filling in the blood between each beating – and reduces the amount of blood to each contract. Before diagnosis of bimirachers, doctors should be able to find patients to have symptoms to diagnose HFPEF and use an ecocardiogram that measures how well your heart is relaxed. The symptoms of symptoms in the early stages of heart muscle health are identified or identified as symptoms of symptoms.
Biomarker – named cBIN1 score or CS short-term physicians measuring muscle deterioration and protein measurement that regulates the heart's ability to both contract and rest. As protein is reduced, CS is growing, serving as a starting heart failure. CS biomarker can be evaluated using simple blood calculations.
The CS biomarker is designed in an outpatient clinical environment. For patients with HFPEF, doctors can use the CS level level and use it as the current medicines, as well as the supply of medicines, and the patient's chances that will be revealed in the hospital for the next 12 months.
"This discovery will enable patients with the most risky patients – including older patients and patients with high blood pressure, diabetes or diabetesmia – examination from their primary care physician during an annual examination," says Eduardo Marbán, MD, MD, Smidt Heart Institute . "This important study has a potential impact on millions of people and serves as a critical means of preventive cardiac care."
Symptoms of heart failure appear to be fatigue, fluid weight gain, swelling of the foot and respiratory deficiencies. Diabetes, diabetes, increased cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes mellitus. Its dissemination in the coming decades has been sharply rising. Previous studies have shown that women are the majority of patients with diagnosed patients.
In the next steps, Cedars-Sinai researchers are planning to identify the specialty populations that can be used by CS biomarker, including sexually-based differences, heart transplant or valve replacement, as well as heart disease or risk factors.
Materials provided Cedars-Sinai Medical Center. Note: Edit content for style and length.